Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Mortality rates in ESRD are unacceptably high. Disorders of mineral metabolism (hyperphosphatemia, hypercalcemia, and secondary hyperparathyroidism) are potentially modifiable. For determining associations among disorders of mineral metabolism, mortality, and morbidity in hemodialysis patients, data on 40,538 hemodialysis patients with at least one determination of serum phosphorus and calcium during the last 3 mo of 1997 were analyzed. Unadjusted, case mix-adjusted, and multivariable-adjusted relative risks of death were calculated for categories of serum phosphorus, calcium, calcium x phosphorus product, and intact parathyroid hormone (PTH) using proportional hazards regression. Also determined was whether disorders of mineral metabolism were associated with all-cause, cardiovascular, infection-related, fracture-related, and vascular access-related hospitalization. After adjustment for case mix and laboratory variables, serum phosphorus concentrations >5.0 mg/dl were associated with an increased relative risk of death (1.07, 1.25, 1.43, 1.67, and 2.02 for serum phosphorus 5.0 to 6.0, 6.0 to 7.0, 7.0 to 8.0, 8.0 to 9.0, and >/=9.0 mg/dl). Higher adjusted serum calcium concentrations were also associated with an increased risk of death, even when examined within narrow ranges of serum phosphorus. Moderate to severe hyperparathyroidism (PTH concentrations >/=600 pg/ml) was associated with an increase in the relative risk of death, whereas more modest increases in PTH were not. When examined collectively, the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperphosphatemia. Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization. Disorders of mineral metabolism are independently associated with mortality and morbidity associated with cardiovascular disease and fracture in hemodialysis patients.

[1]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[2]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[3]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  A. LaCroix,et al.  Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study , 2003, Annals of Internal Medicine.

[6]  Francesco Locatelli,et al.  Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2003, The New England journal of medicine.

[7]  K. Kalantar-Zadeh,et al.  Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. , 2003, Kidney international.

[8]  N. Chen,et al.  Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. , 2003, Kidney international.

[9]  B. Kestenbaum,et al.  Risk of hip fracture among dialysis and renal transplant recipients. , 2002, JAMA.

[10]  F. Port,et al.  Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. , 2002, Kidney international.

[11]  A. Collins.  Influence of target hemoglobin in dialysis patients on morbidity and mortality. , 2002, Kidney international. Supplement.

[12]  P. Raggi,et al.  Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? , 2002, Journal of the American College of Cardiology.

[13]  P. Fein,et al.  Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  F. Llach,et al.  Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  S. Ganesh,et al.  Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.

[16]  M. Coco,et al.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  D. Churchill,et al.  Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  Craig S. Wong,et al.  Risk factors for hip fracture among patients with end-stage renal disease. , 2000, Kidney international.

[19]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[20]  J A Sargent,et al.  Whither goest Kt/V? , 2000, Kidney international. Supplement.

[21]  G. London,et al.  Arterial stiffening and vascular calcifications in end-stage renal disease. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  E. Lowrie,et al.  Comparing the urea reduction ratio and the urea product as outcome-based measures of hemodialysis dose. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  W. Owen,et al.  Exploring the reverse J-shaped curve between urea reduction ratio and mortality. , 1999, Kidney international.

[24]  W. Owen,et al.  Dose of hemodialysis and survival: differences by race and sex. , 1998, JAMA.

[25]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  N. Mittman,et al.  Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  W. McClellan,et al.  Early death in dialysis patients: risk factors and impact on incidence and mortality rates. , 1996, Journal of the American Society of Nephrology : JASN.

[29]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[30]  D. Churchill,et al.  Canadian Hemodialysis Morbidity Study. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  E G Lowrie,et al.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  M. Pauly,et al.  Survival analysis of patients undergoing dialysis. , 1987, JAMA.

[33]  R. Wolfe,et al.  Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  R. Wolfe,et al.  Body size, dose of hemodialysis, and mortality. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  David C. Murray,et al.  Hypocalcemia, morbidity, and mortality in end-stage renal disease. , 1996, American journal of nephrology.

[36]  D. Collett.  Modelling survival data , 1994 .

[37]  D.,et al.  Regression Models and Life-Tables , 2022 .